Evidence map›Paper›PMID 38310290›Full record

ArticleTrials2024

Anticipating and strategizing to address potential bottlenecks during clinical research projects in sub-Saharan Africa: a case for adapting approaches and tools used in the entrepreneurial and development sectors.

Yauba Saidu, Sangwe Clovis Nchinjoh, Amani Adidja, Andreas Frambo Besong, Palmer Masumbe Netongo, Paul Ndom, Marya Liebermann

Abstract readLetter
In one paragraph

Article in Trials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yauba SaiduClinton Health Access Initiative Inc, PO Box 2664, Yaoundé, Cameroon. ysaidu@clintonhealthaccess.org.ORCID http://orcid.org/0000-0002-0571-0074
Sangwe Clovis NchinjohClinton Health Access Initiative Inc, PO Box 2664, Yaoundé, Cameroon.
Amani AdidjaFaculté de Médecine Et de Sciences Biomédicales de L, Université de Yaoundé I (FMSB-UYI), Yaoundé, Cameroon.
Andreas Frambo BesongClinton Health Access Initiative Inc, PO Box 2664, Yaoundé, Cameroon.
Palmer Masumbe NetongoFaculty of Life Sciences, University of Yaoundé 1, Yaoundé, Cameroon.
Paul NdomFaculté de Médecine Et de Sciences Biomédicales de L, Université de Yaoundé I (FMSB-UYI), Yaoundé, Cameroon.
Marya LiebermannDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, South Bend, IN, USA.

Funding

Point of use detection of low-quality pharmaceutical asparaginaseU01CA269195 · NCI · UNIVERSITY OF NOTRE DAME · PI Marya Lieberman · 2022 to 2026
$2.6M
NCI NIH HHS U01 CA269195
6 · The paper itself

Abstract

Many research funders have invested billions of US dollars in building research capacity in sub-Saharan Africa (SSA). Despite these colossal investments, many well-intentioned and designed clinical research projects have either failed to kick off or ended abruptly. Although obstacles to clinical research in SSA are well known, there is limited information on frameworks and tools that can be used to anticipate and avert these systemic bottlenecks, particularly those related to socio-politics. In this paper, we leveraged lessons from entrepreneurs and development experts in harsh and uncertain business environments to develop a framework for anticipating and addressing potential bottlenecks to clinical research in SSA. More so, to illustrate and build a case for this framework, we shared our experience in supporting clinicians and regulators to adopt a point-of-use care tool, the "chemoPAD," to screen for the quality of anticancer medications rapidly and systematically in Cameroon despite resistance from some stakeholders. The critical steps in this framework involve identifying stakeholders, categorizing them based on their potential reactions to the study (adversary, supporters, and indifferents), and developing critical strategies to engage or deal with each stakeholder's reactions, starting with adversaries. This approach may be useful in complex research projects, especially clinical trials, which often involve many stakeholders with different interests and perceptions.

Indexed as

Biomedical ResearchAfrica South of the SaharaCapacity BuildingEntrepreneurshipHumans

Identifiers

PMID38310290
PMCPMC10837968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.